Aura Biosciences (NASDAQ:AURA - Get Free Report) was upgraded by equities researchers at Lifesci Capital to a "strong-buy" rating in a report issued on Friday,Zacks.com reports.
Several other analysts have also recently issued reports on AURA. BTIG Research increased their target price on Aura Biosciences from $21.00 to $24.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Cowen reissued a "buy" rating on shares of Aura Biosciences in a research report on Friday, October 18th. Scotiabank raised their price objective on Aura Biosciences from $20.00 to $23.00 and gave the stock a "sector outperform" rating in a research report on Friday, October 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $23.00.
Read Our Latest Stock Report on AURA
Aura Biosciences Trading Up 2.9 %
Shares of NASDAQ AURA traded up $0.22 during midday trading on Friday, hitting $7.90. The company's stock had a trading volume of 60,402 shares, compared to its average volume of 128,489. The business's 50 day moving average is $8.28 and its two-hundred day moving average is $8.90. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38. The firm has a market cap of $394.61 million, a P/E ratio of -4.56 and a beta of 0.29.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02. On average, analysts predict that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Los Pinos Elisabet De sold 15,955 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Janet Jill Hopkins sold 11,822 shares of the firm's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the transaction, the insider now owns 151,693 shares of the company's stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,778 shares of company stock worth $240,706 in the last 90 days. Insiders own 5.40% of the company's stock.
Hedge Funds Weigh In On Aura Biosciences
A number of institutional investors have recently modified their holdings of AURA. Franklin Resources Inc. raised its stake in shares of Aura Biosciences by 14.8% during the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company's stock valued at $15,571,000 after buying an additional 215,597 shares during the last quarter. Wellington Management Group LLP purchased a new position in shares of Aura Biosciences during the 3rd quarter valued at about $1,037,000. Barclays PLC raised its stake in shares of Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after buying an additional 43,897 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company's stock valued at $1,892,000 after buying an additional 41,711 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock valued at $8,990,000 after buying an additional 39,379 shares during the last quarter. Hedge funds and other institutional investors own 96.75% of the company's stock.
About Aura Biosciences
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Articles
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
